¼¼°èÀÇ ÀÌ»óÁöÁúÇ÷Áõ Ä¡·áÁ¦ ½ÃÀå
Dyslipidemia Drugs
»óǰÄÚµå : 1757695
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 06¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 268 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,053,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,161,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

ÀÌ»óÁöÁúÇ÷Áõ Ä¡·áÁ¦ ¼¼°è ½ÃÀåÀº 2030³â±îÁö ¹Ì±¹¿¡¼­ 405¾ï ´Þ·¯¿¡ ´ÞÇÒ Àü¸Á

2024³â¿¡ 249¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â ÀÌ»óÁöÁúÇ÷Áõ Ä¡·áÁ¦ ¼¼°è ½ÃÀåÀº ºÐ¼® ±â°£ÀÎ 2024-2030³â¿¡ CAGR 8.4%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 405¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ ºñ½ºÅ¸Æ¾°è ¾àÁ¦´Â CAGR 9.7%¸¦ ±â·ÏÇÏ¸ç ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 288¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ½ºÅ¸Æ¾°è ¾àÁ¦ ºÎ¹®ÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ µ¿¾È CAGR 5.7%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 68¾ï ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 13.4%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ ÀÌ»óÁöÁúÇ÷Áõ Ä¡·áÁ¦ ½ÃÀåÀº 2024³â¿¡ 68¾ï ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ °æÁ¦ ´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 89¾ï ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ºÐ¼® ±â°£ÀÎ 2024-2030³â CAGRÀº 13.4%¸¦ ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖ°í, ºÐ¼® ±â°£ µ¿¾È CAGRÀº °¢°¢ 4.2%¿Í 8.1%·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 5.6%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°èÀÇ ÀÌ»óÁöÁúÇ÷Áõ Ä¡·áÁ¦ ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

ÀÌ»óÁöÁúÇ÷Áõ Ä¡·áÁ¦°¡ ½ÉÇ÷°üÁúȯ °ü¸®ÀÇ ÃÖÀü¼±¿¡ ÀÖ´Â ÀÌÀ¯´Â ¹«¾ùÀϱî?

ÀÌ»óÁöÁúÇ÷Áõ Ä¡·áÁ¦´Â ½ÉÇ÷°ü°è Áúȯ(CVD)ÀÇ ¿¹¹æ°ú Ä¡·á¿¡ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. ÀÌ»óÁöÁúÇ÷ÁõÀº Ç÷Áß ÁöÁú, ƯÈ÷ LDL ÄÝ·¹½ºÅ×·Ñ(³ª»Û ÄÝ·¹½ºÅ×·Ñ)ÀÇ »ó½Â, HDL ÄÝ·¹½ºÅ×·Ñ(ÁÁÀº ÄÝ·¹½ºÅ×·Ñ)ÀÇ ÀúÇÏ, Áß¼ºÁö¹æ(Áß¼ºÁö¹æ)ÀÇ Áõ°¡¸¦ Ư¡À¸·Î Çϸç, µ¿¸Æ°æÈ­ ¹× ±âŸ ½ÉÀå °ü·Ã ÇÕº´Áõ ¹ßº´¿¡ Å©°Ô °ü¿©ÇÕ´Ï´Ù. ÁÂ½Ä »ýȰ, ½Ä½À°ü Àå¾Ö, ºñ¸¸, Á¦2Çü ´ç´¢º´°ú °°Àº »ýȰ½À°ü °ü·Ã À§Çè¿äÀÎÀÌ Àü ¼¼°èÀûÀ¸·Î È®»êµÊ¿¡ µû¶ó ÀÌ»óÁöÁúÇ÷Áõ ¹ßº´·üÀº ƯÈ÷ °í·ÉÈ­ Àα¸ Áý´Ü°ú ½ÅÈï±¹ÀÇ ÀþÀº Àα¸ Áý´Ü ¸ðµÎ¿¡¼­ ±ÞÁõÇϰí ÀÖ½À´Ï´Ù. ½ºÅ¸Æ¾, PCSK9 ¾ïÁ¦Á¦, ´ãÁó»ê ºÐºñ ¾ïÁ¦Á¦, ÇǺ극ÀÌÆ®, ´Ï¾Æ½Å, º¨Æäµµ»ê°ú °°Àº »õ·Î¿î ¾à¹°Àº ÁöÁú ¼öÄ¡¸¦ °ü¸®Çϰí, ÇöóÅ© ÃàÀûÀ» ¾ïÁ¦Çϸç, ±Ã±ØÀûÀ¸·Î ½ÉÀ帶ºñ ¹× ³úÁ¹Áß À§ÇèÀ» ³·Ãߴµ¥ ÇʼöÀûÀÎ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. ¿¹¹æ»Ó¸¸ ¾Æ´Ï¶ó, ÀÌ·¯ÇÑ ¾à¹°Àº 2Â÷ ¿¹¹æ, Áï ÀÌ¹Ì ½ÉÇ÷°ü°è ÁúȯÀ» ¾Î°í Àִ ȯÀÚ°¡ Àç¹ßÀ» ÇÇÇÒ ¼ö ÀÖµµ·Ï µ½´Â µ¥¿¡µµ Á¡Á¡ ´õ ¸¹ÀÌ »ç¿ëµÇ°í ÀÖ½À´Ï´Ù. ¹Ì±¹½ÉÀåÇÐȸ(ACC)¿Í À¯·´½ÉÀåÇÐȸ(ESC)¿Í °°Àº ´ÜüÀÇ °¡À̵å¶óÀÎÀº Àû±ØÀûÀÎ ÁöÁú °­ÇÏ Àü·«À» Áö¼ÓÀûÀ¸·Î °­Á¶Çϰí ÀÖÀ¸¸ç, ÀÓ»ó°ú ¿Ü·¡ ¸ðµÎ¿¡¼­ ¾à¸®ÇÐÀû °³ÀÔÀÇ ¿ªÇÒÀ» °­È­Çϰí ÀÖ½À´Ï´Ù. Ä¡·áµÇÁö ¾ÊÀº ÀÌ»óÁöÁúÇ÷ÁõÀÇ À§Çè¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö°í Áø´Ü¿¡ ´ëÇÑ Á¢±Ù¼ºÀÌ °³¼±µÊ¿¡ µû¶ó ÀÌ»óÁöÁúÇ÷Áõ Ä¡·áÁ¦¿¡ ´ëÇÑ ¼¼°è ¼ö¿ä´Â ºü¸£°Ô Áõ°¡Çϰí ÀÖ½À´Ï´Ù.

°úÇÐÀÇ ¹ßÀü°ú ¾à¹° Çõ½ÅÀÌ ÀÌ»óÁöÁúÇ÷Áõ Ä¡·áÀÇ Àü¸ÁÀ» ¾î¶»°Ô Çü¼ºÇϰí Àִ°¡?

ÀÌ»óÁöÁúÇ÷Áõ Ä¡·áÁ¦ ½ÃÀåÀº º¸´Ù È¿°úÀûÀ̰í Ç¥ÀûÈ­µÇ°í ¾ÈÀü¼ºÀÌ ³ôÀº Ä¡·á¹ýÀ» °³¹ßÇÒ ¼ö ÀÖ´Â °úÇÐÀû Áøº¸·Î ÀÎÇØ ÀçÆíµÇ°í ÀÖ½À´Ï´Ù. ±âÁ¸ÀÇ ½ºÅ¸Æ¾ °è¿­ ¾à¹°Àº ±× È¿°ú¿Í ºñ¿ë È¿À²¼ºÀÌ ÀÔÁõµÇ¾î ¿©ÀüÈ÷ 1Â÷ ¼±Åà ¾à¹°ÀÌÁö¸¸, Â÷¼¼´ë Ä¡·áÁ¦¿¡ ÀÇÇØ º¸¿ÏµÇ°í ÀÖÀ¸¸ç, °æ¿ì¿¡ µû¶ó¼­´Â µµÀüÀ» ¹Þ°í ÀÖ½À´Ï´Ù. ¾Ë¸®·ÎÄí¸¿°ú ¿¡º¼·ÎÄí¸¿°ú °°Àº PCSK9 ¾ïÁ¦Á¦´Â LDL ¼ö¿ëüÀÇ ºÐÇØ¸¦ ¸·´Â ´ÜÀÏŬ·Ð Ç×ü¸¦ ÀÌ¿ëÇÏ¿© ½ºÅ¸Æ¾ ºÒ³»¼º ȯÀÚ³ª Ãß°¡ÀûÀÎ ÁöÁú Á¶ÀýÀÌ ÇÊ¿äÇÑ È¯ÀÚ¿¡°Ô °­·ÂÇÑ ÄÝ·¹½ºÅ×·Ñ °­ÇÏ È¿°ú¸¦ Á¦°øÇÕ´Ï´Ù. ¶ÇÇÑ, ÃÖ±Ù ½ÂÀÎµÈ ÀÎŬ¸®½Ã¶õ°ú °°Àº siRNA(small interfering RNA) ¿ä¹ýÀº À¯ÀüÀÚ ¼öÁØ¿¡¼­ PCSK9¸¦ Ç¥ÀûÀ¸·Î ÇÏ´Â »õ·Î¿î ¸ÞÄ¿´ÏÁòÀ» µµÀÔÇÏ¿© Åõ¿© °£°ÝÀ» ¿¬ÀåÇϰí ȯÀÚÀÇ ¼øÀÀµµ¸¦ °³¼±ÇÒ ¼ö ÀÖ½À´Ï´Ù. ´Ù¸¥ »õ·Î¿î ¾à¹°·Î´Â º£¹«Æäµµ»ê°ú °°Àº ATP ½ÃÆ®¸£»ê ¸®¾ÆÁ¦ ¾ïÁ¦Á¦°¡ Àִµ¥, ÀÌ´Â ±âÁ¸ Ä¡·áÁ¦·Î ºÎÀÛ¿ëÀ» °æÇèÇÑ È¯Àڵ鿡°Ô ´ë¾ÈÀÌ µÉ ¼ö ÀÖ½À´Ï´Ù. º´¿ë¿ä¹ý ¶ÇÇÑ °íÁ¤ ¿ë·® ¿ä¹ýÀ» ÅëÇØ È¿´ÉÀ» °³¼±ÇÏ°í ¾à¹°ÀÇ ºÎ´ãÀ» ÁÙÀÏ ¼ö ÀÖ¾î Àα⸦ ²ø°í ÀÖ½À´Ï´Ù. ÁöÁú ¼öÄ¡»Ó¸¸ ¾Æ´Ï¶ó ¿°Áõ°ú ÇöóÅ© ¾ÈÁ¤¼ºÀ» Ä¡·á Ç¥ÀûÀ¸·Î »ï´Â »õ·Î¿î ¿¬±¸°¡ ÁøÇàµÇ¸é¼­ µ¿¸Æ°æÈ­¼º ÁúȯÀÇ ÁøÇà¿¡ ´ëÇÑ º¸´Ù Æø³ÐÀº ÀÌÇØ°¡ ÀÌ·ç¾îÁö°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ »õ·Î¿î ¾à¹°À» Æò°¡ÇÏ´Â ÀÓ»ó½ÃÇèÀº ÁöÁú °ü¸®»Ó¸¸ ¾Æ´Ï¶ó ½ÇÁ¦ ½ÉÇ÷°ü°è °á°ú¿¡¼­µµ À¯¸ÁÇÑ °á°ú¸¦ º¸¿©ÁÜÀ¸·Î½á º¸´Ù Á¾ÇÕÀûÀÎ Ä¡·á Á¢±Ù¹ýÀ¸·ÎÀÇ ÀüȯÀ» º¸¿©ÁÖ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Çõ½ÅÀº Ç¥ÁØ Ä¡·á¸¦ ÀçÁ¤ÀÇÇϰí, ÀÓ»óÀÇ¿Í È¯ÀÚ°¡ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â Ä¡·á ¿É¼ÇÀ» È®´ëÇϰí ÀÖ½À´Ï´Ù.

ÀÌ»óÁöÁúÇ÷Áõ Ä¡·áÁ¦ÀÇ »ç¿ëÀº Áö¿ª°ú ȯÀÚ±º¿¡ µû¶ó ´Ù¸¥ ÀÌÀ¯´Â ¹«¾ùÀΰ¡?

Àü ¼¼°è ÀÌ»óÁöÁúÇ÷Áõ Ä¡·áÁ¦ÀÇ »ç¿ë ÆÐÅÏÀº Áö¿ªÀÇ ÀÇ·á ÀÎÇÁ¶ó, °æÁ¦ »óȲ, Áø´Ü ´É·Â, °Ç°­ ÀνĿ¡ µû¶ó Å©°Ô ´Þ¶óÁý´Ï´Ù. ¹Ì±¹, ij³ª´Ù, µ¶ÀÏ, ÀϺ»°ú °°Àº °í¼Òµæ ±¹°¡¿¡¼­´Â °íµµÀÇ °ËÁø ÇÁ·Î±×·¥, È®¸³µÈ ÀÓ»ó °¡À̵å¶óÀÎ, ó¹æ¾à¿¡ ´ëÇÑ ±¤¹üÀ§ÇÑ Á¢±Ù¼ºÀ¸·Î ÀÎÇØ ÀÌ»óÁöÁúÇ÷Áõ Ä¡·á´Â ¿¹¹æ ÀÇ·áÀÇ ÀÏ»óÀûÀÎ Ãø¸éÀ¸·Î ÀÚ¸® Àâ¾Ò½À´Ï´Ù. À̵é Áö¿ª¿¡¼­´Â ½ºÅ¸Æ¾ °è¿­ ¾à¹°ÀÇ Ã³¹æÀÌ ÁÖ·ù¸¦ ÀÌ·ç°í ÀÖÁö¸¸, PCSK9 ¾ïÁ¦Á¦¿Í °°Àº »õ·Î¿î Ä¡·á¾à¹°µµ º¸Çè Àû¿ë È®´ë¿Í Àü¹®ÀÇÀÇ Áõ°¡·Î ±× ÀÔÁö¸¦ ´ÙÁ®°¡°í ÀÖ½À´Ï´Ù. ¹Ý¸é, ÁßÀú¼Òµæ ±¹°¡¿¡¼­´Â Áø´Ü ºÎÁ·, °í±Þ ÁöÁú °Ë»ç¿¡ ´ëÇÑ Á¢±Ù¼º Á¦ÇÑ, ³·Àº 1Àδç ÀÇ·áºñ µîÀÇ ¹®Á¦¿¡ Á÷¸éÇÏ´Â °æ¿ì°¡ ¸¹½À´Ï´Ù. ±× °á°ú, ¸¹Àº ÀÌ»óÁöÁúÇ÷Áõ ȯÀÚµéÀÌ Ä¡·á¹ÞÁö ¸øÇÑ Ã¤ ¹æÄ¡µÇ°Å³ª, ±¸½Ä Ä¡·á¹ýÀ̳ª È¿°ú°¡ ³·Àº Ä¡·á¹ýÀ¸·Î °ü¸®µÇ°í ÀÖ½À´Ï´Ù. ¾à¹° Ä¡·á¸¦ µÑ·¯½Ñ ¹®È­Àû ÀνÄ, ºÎÀÛ¿ë¿¡ ´ëÇÑ ¿ì·Á, º¹¾à ¼øÀÀµµ ¹®Á¦µµ º¹¾à ¼øÀÀµµ¿Í Àå±âÀûÀÎ Ä¡·á ¼º°ø¿¡ ¿µÇâÀ» ¹ÌĨ´Ï´Ù. ¿©·¯ À§Çè ¿äÀÎÀ» °¡Áø ³ëÀÎÀº Àû±ØÀûÀÎ Ä¡·á ¿ä¹ýÀÌ Àû¿ëµÉ °¡´É¼ºÀÌ ³ôÀº ¹Ý¸é, ÀþÀº ȯÀÚ³ª ¹«Áõ»ó ȯÀÚ´Â ½ÉÇ÷°ü Áõ»óÀÌ ³ªÅ¸³¯ ¶§±îÁö °£°úµÉ ¼ö ÀÖ½À´Ï´Ù. ¼ºº°µµ ÇÑ ¿äÀÎÀ¸·Î ÀÛ¿ëÇϴµ¥, ¿¬±¸¿¡ µû¸£¸é ¿©¼ºÀº ³²¼º¿¡ ºñÇØ ½ÉÇ÷°ü À§Çè¿¡ ´ëÇÑ Áø´Ü°ú Ä¡·á°¡ Á¦´ë·Î ÀÌ·ç¾îÁöÁö ¾Ê´Â °æ¿ì°¡ ´õ ¸¹½À´Ï´Ù. ÀÌ·¯ÇÑ °ÝÂ÷´Â Àü ¼¼°èÀûÀ¸·Î °øÆòÇϰí ÀϰüµÈ ÀÌ»óÁöÁúÇ÷Áõ °ü¸®¸¦ ÃËÁøÇϱâ À§ÇÑ °øÁߺ¸°Ç Ä·ÆäÀÎ, ÀÇ»ç ±³À°, Á¤Ã¥ °³ÇõÀÇ Á߿伺À» °­Á¶Çϰí ÀÖ½À´Ï´Ù.

¼¼°è ÀÌ»óÁöÁúÇ÷Áõ Ä¡·áÁ¦ ½ÃÀåÀÇ ¼ºÀåÀ» ÃËÁøÇÏ´Â ÁÖ¿ä ¿äÀÎÀº ¹«¾ùÀΰ¡?

ÀÌ»óÁöÁúÇ÷Áõ Ä¡·áÁ¦ ½ÃÀåÀÇ ¼ºÀåÀº ½ÉÇ÷°üÁúȯ ÅðÄ¡¸¦ À§ÇÑ Àü ¼¼°èÀÇ ³ë·ÂÀ» ¹Ý¿µÇÏ´Â ¿ªÇÐ, ÀÓ»ó, ±â¼ú, °æÁ¦Àû ÃËÁø¿äÀÎÀÇ Á¶ÇÕ¿¡ ÀÇÇØ ÃËÁøµÇ°í ÀÖ½À´Ï´Ù. ÁÖ¿ä ¼ºÀå ¿äÀÎÀº Àα¸ °í·ÉÈ­, ´ç´¢º´ ¹× ºñ¸¸ Áõ°¡, ¾É¾Æ¼­ »ýȰÇÏ°í °¡°ø½ÄǰÀ» ¼±È£ÇÏ´Â µµ½Ã »ýȰ¾ç½ÄÀÇ º¯È­¿Í ¹ÐÁ¢ÇÑ °ü·ÃÀÌ ÀÖ´Â ÀÌ»óÁöÁúÇ÷Áõ Áõ°¡ÀÔ´Ï´Ù. ÁøÈ­ÇÏ´Â ÀÓ»ó °¡À̵å¶óÀΰú À§Çè °èÃþÈ­ µµ±¸·Î µÞ¹ÞħµÇ´Â ¿¹¹æÀû ½ÉÀ庴Çп¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁü¿¡ µû¶ó Á¶±â °ËÁø°ú Àû±ØÀûÀÎ ÁöÁú °ü¸® Àü·«À» ÅëÇØ ¾à¹° Ä¡·á¸¦ ¹ÞÀ» ¼ö Àִ ȯÀÚ±ºÀÌ È®´ëµÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, °øÁß º¸°Ç¿¡ ´ëÇÑ ³ë·Â°ú Á¦¾à»çÀÇ ¼ÒºñÀÚ Á÷Á¢ ÆÇ¸Å·Î ÀÎÇØ ½ÉÇ÷°ü °Ç°­¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö¸é¼­ ´õ ¸¹Àº ȯÀÚµéÀÌ Àû±ØÀûÀ¸·Î Ä¡·á¸¦ ¹Þ°í ÀÖ½À´Ï´Ù. º¸Çè »óȯ Á¤Ã¥µµ °³¼±µÇ°í ÀÖÀ¸¸ç, ÀÓ»óÀû À¯¿ë¼ºÀÌ ÀÔÁõµÇ°í Àå±âÀûÀÎ ÀÇ·áºñ¿ëÀ» Àý°¨ÇÒ ¼ö ÀÖ´Â »õ·Î¿î Ä¡·á¹ý¿¡ ´ëÇØ º¸Çèȸ»ç°¡ º¸ÇèÀ» Àû¿ëÇϰí ÀÖ½À´Ï´Ù. ±â¼ú Çõ½Å Ãø¸é¿¡¼­´Â Â÷¼¼´ë »ý¹°ÇÐÀû Á¦Á¦, À¯ÀüÀÚ Ä¡·áÁ¦, º¹ÇÕÁ¦ µî °­·ÂÇÑ ÆÄÀÌÇÁ¶óÀÎÀÌ Á¦¾à ´ë±â¾÷°ú ¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö ±â¾÷À¸·ÎºÎÅÍ ¸¹Àº ÅõÀÚ¸¦ À¯Ä¡Çϰí ÀÖ½À´Ï´Ù. ¿ø°Ý ¸ð´ÏÅ͸µ, °³ÀÎÈ­µÈ ÀÇ·á Ç÷§Æû, AI ±â¹Ý ÀÇ»ç°áÁ¤ Áö¿ø µµ±¸¿Í °°Àº µðÁöÅÐ Çコ ±â¼úÀº Ä¡·áÀÇ °³ÀÎÈ­ ¹× ¼øÀÀµµ¸¦ ´õ¿í °­È­Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¸ðµç ¿äÀεéÀÌ º¹ÇÕÀûÀ¸·Î ÀÛ¿ëÇÏ¿© ÀÌ»óÁöÁúÇ÷Áõ Ä¡·áÁ¦ ½ÃÀåÀÌ ¿ªµ¿ÀûÀ¸·Î ¼ºÀåÇϰí ÀÖÀ¸¸ç, ÀÌ´Â ¼øÈ¯±â ÁúȯÀÇ ÀÌȯÀ²°ú »ç¸Á·üÀ» ³·Ãß±â À§ÇÑ ¼¼°è Àü·«¿¡¼­ Á¡Á¡ ´õ Áß½ÉÀûÀÎ ¿ªÇÒÀ» ÇÏ°Ô µÉ °ÍÀÔ´Ï´Ù.

ºÎ¹®

¾à¹° À¯Çü(ºñ½ºÅ¸Æ¾°è ¾àÁ¦, ½ºÅ¸Æ¾°è ¾àÁ¦), ¿ëµµ(º´¿ø ¾à±¹, ¼Ò¸Å ¾à±¹, ±âŸ ¿ëµµ)

Á¶»ç ´ë»ó ±â¾÷ »ç·Ê(ÃÑ 34°³»ç)

AI ÅëÇÕ

¿ì¸®´Â °ËÁõµÈ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AI ÅøÀ» ÅëÇØ ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ Çõ½ÅÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â LLM ¹× »ê¾÷º° SLM Äõ¸®¸¦ µû¸£´Â ´ë½Å ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ¹æ´ëÇÑ ¾çÀÇ ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»çÀÇ ±¹°¡, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±â¹ÝÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¸ÅÃâ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº °¨¼Ò, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû ¹× °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

ksm
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Dyslipidemia Drugs Market to Reach US$40.5 Billion by 2030

The global market for Dyslipidemia Drugs estimated at US$24.9 Billion in the year 2024, is expected to reach US$40.5 Billion by 2030, growing at a CAGR of 8.4% over the analysis period 2024-2030. Non-Statins Drugs, one of the segments analyzed in the report, is expected to record a 9.7% CAGR and reach US$28.8 Billion by the end of the analysis period. Growth in the Statins Drugs segment is estimated at 5.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$6.8 Billion While China is Forecast to Grow at 13.4% CAGR

The Dyslipidemia Drugs market in the U.S. is estimated at US$6.8 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$8.9 Billion by the year 2030 trailing a CAGR of 13.4% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 4.2% and 8.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.6% CAGR.

Global Dyslipidemia Drugs Market - Key Trends & Drivers Summarized

Why Are Dyslipidemia Drugs at the Forefront of Cardiovascular Disease Management?

Dyslipidemia drugs play a pivotal role in the prevention and treatment of cardiovascular diseases (CVDs), which remain the leading cause of death worldwide. Dyslipidemia, characterized by abnormal levels of lipids in the blood-particularly elevated LDL cholesterol (the "bad" cholesterol), low HDL cholesterol (the "good" cholesterol), and high triglycerides-contributes significantly to the development of atherosclerosis and other heart-related complications. As lifestyle-related risk factors such as sedentary behavior, poor diet, obesity, and type 2 diabetes become more prevalent globally, the incidence of dyslipidemia has surged, particularly in both aging populations and younger cohorts in emerging economies. Drugs like statins, PCSK9 inhibitors, bile acid sequestrants, fibrates, niacin, and newer agents like bempedoic acid have become essential for managing lipid levels, reducing plaque buildup, and ultimately lowering the risk of heart attacks and strokes. Beyond prevention, these medications are increasingly used in secondary prevention-helping patients with existing cardiovascular issues avoid recurrence. The guidelines by organizations such as the American College of Cardiology (ACC) and the European Society of Cardiology (ESC) continue to stress aggressive lipid-lowering strategies, thereby reinforcing the role of pharmacologic intervention in both clinical and outpatient settings. As awareness grows about the risks of untreated dyslipidemia and access to diagnostics improves, the global demand for dyslipidemia drugs is expanding rapidly.

How Are Scientific Advancements and Drug Innovations Shaping the Dyslipidemia Therapeutic Landscape?

The dyslipidemia drug market is being reshaped by significant scientific advancements that are leading to the development of more effective, targeted, and safer treatments. Traditional statins, though still the first-line therapy due to their well-established efficacy and cost-effectiveness, are being complemented and, in some cases, challenged by next-generation therapies. PCSK9 inhibitors such as alirocumab and evolocumab, which use monoclonal antibodies to prevent the degradation of LDL receptors, offer powerful cholesterol-lowering effects for patients who are statin-intolerant or require additional lipid control. Additionally, the recent approval of small interfering RNA (siRNA) therapies like inclisiran introduces a novel mechanism that targets PCSK9 at the genetic level, allowing for longer dosing intervals and improved patient adherence. Other emerging agents include ATP citrate lyase inhibitors like bempedoic acid, which provide alternatives for those experiencing side effects with traditional options. Combination therapies are also gaining traction, with fixed-dose regimens improving efficacy and reducing pill burden. Beyond lipid levels, new research is focusing on inflammation and plaque stability as therapeutic targets, signaling a broader understanding of atherosclerotic disease progression. Clinical trials evaluating these novel agents are showing promising results not only in lipid management but also in actual cardiovascular outcomes, indicating a shift toward more holistic treatment approaches. These innovations are redefining the standard of care and expanding the treatment options available to clinicians and patients alike.

Why Does Dyslipidemia Drug Usage Vary Across Regions and Patient Demographics?

The global usage patterns of dyslipidemia drugs vary widely based on regional healthcare infrastructure, economic status, diagnostic capabilities, and population health awareness. In high-income countries such as the United States, Canada, Germany, and Japan, advanced screening programs, well-established clinical guidelines, and widespread access to prescription medications have made dyslipidemia treatment a routine aspect of preventive healthcare. In these regions, statins dominate prescriptions, but newer therapies like PCSK9 inhibitors are gaining ground due to better insurance coverage and growing specialist use. In contrast, low- and middle-income countries often face challenges related to underdiagnosis, limited access to advanced lipid testing, and lower healthcare expenditure per capita. As a result, many cases of dyslipidemia remain untreated or are managed with outdated or less effective therapies. Cultural perceptions around medication, side effect concerns, and compliance issues also influence adherence and long-term treatment success. Age and comorbid conditions further shape prescribing trends-older adults with multiple risk factors are more likely to be placed on aggressive treatment regimens, while younger or asymptomatic individuals may be overlooked until cardiovascular symptoms arise. Gender also plays a role, as studies suggest women are often underdiagnosed or undertreated for cardiovascular risk compared to men. These disparities underscore the importance of public health campaigns, physician education, and policy reforms aimed at promoting equitable and consistent management of dyslipidemia on a global scale.

What Are the Key Drivers Fueling Growth in the Global Dyslipidemia Drugs Market?

The growth in the dyslipidemia drugs market is fueled by a combination of epidemiological, clinical, technological, and economic drivers that reflect a global effort to combat cardiovascular disease. A primary growth driver is the rising global burden of dyslipidemia, which is closely tied to aging populations, increased rates of diabetes and obesity, and urban lifestyle shifts that favor sedentary behavior and processed diets. The growing emphasis on preventive cardiology-backed by evolving clinical guidelines and risk stratification tools-is encouraging earlier screening and more aggressive lipid management strategies, thereby expanding the patient pool eligible for pharmacotherapy. Additionally, heightened awareness about cardiovascular health, driven by both public health initiatives and direct-to-consumer marketing by pharmaceutical companies, is prompting more individuals to seek treatment proactively. Reimbursement policies are also improving, with insurers increasingly covering newer, high-cost therapies in light of their proven clinical benefits and reduced long-term healthcare costs. On the innovation front, robust pipelines featuring next-generation biologics, gene therapies, and combination products are drawing significant investment from pharmaceutical giants and biotech firms alike. Digital health technologies, including remote monitoring, personalized medicine platforms, and AI-driven decision support tools, are further enhancing treatment personalization and adherence. All these factors are converging to create a dynamic and expanding market for dyslipidemia drugs-one that is set to play an increasingly central role in the global strategy to reduce cardiovascular morbidity and mortality.

SCOPE OF STUDY:

The report analyzes the Dyslipidemia Drugs market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Drug Type (Non-Statins Drugs, Statins Drugs); Application (Hospital Pharmacy, Retail Pharmacy, Other Applications)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 34 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â